• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

星状神经节阻滞改善系统性硬化症患者的肢端循环

Improvement of acral circulation in a patient with systemic sclerosis with stellate blocks.

作者信息

Klyscz T, Jünger M, Meyer H, Rassner G

机构信息

Department of Dermatology, University of Tübingen, Germany.

出版信息

Vasa. 1998 Feb;27(1):39-42.

PMID:9540432
Abstract

We report on a 77-year-old male patient with systemic sclerosis. He suffered from secondary Raynaud's phenomenon on the basis of systemic sclerosis. Medical treatment in the past, including the administration of calcium-channel blockers, pentoxifylline and intravenous prostaglandin therapy, was unsuccessful and the clinical situation became worse. In a final effort stellate blocks were performed over a period of several weeks and, for the first time, there was lasting clinical benefit. Complaints and Raynaud's attacks abated significantly, as documented by local cold exposure tests. Therapeutic benefit from stellate blocks in a patient with systemic sclerosis is described here for the first time.

摘要

我们报告了一名77岁的系统性硬化症男性患者。他患有基于系统性硬化症的继发性雷诺现象。过去的医学治疗,包括使用钙通道阻滞剂、己酮可可碱和静脉注射前列腺素治疗,均未成功,临床状况恶化。在最后的努力中,在数周内进行了星状神经节阻滞,首次获得了持久的临床益处。如局部冷暴露试验所记录,症状和雷诺发作明显减轻。本文首次描述了星状神经节阻滞对系统性硬化症患者的治疗益处。

相似文献

1
Improvement of acral circulation in a patient with systemic sclerosis with stellate blocks.星状神经节阻滞改善系统性硬化症患者的肢端循环
Vasa. 1998 Feb;27(1):39-42.
2
Adverse effects of stellate ganglion block on Raynaud's phenomenon associated with progressive systemic sclerosis.星状神经节阻滞对与进行性系统性硬化症相关的雷诺现象的不良反应。
Anesth Analg. 1993 Nov;77(5):1057-60. doi: 10.1213/00000539-199311000-00031.
3
Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.静脉注射伊洛前列素治疗系统性硬化症继发的雷诺现象和缺血性溃疡。
J Rheumatol. 1992 Sep;19(9):1407-14.
4
[Polarized light irradiation near the stellate ganglion in a patient with Raynaud's sign].[雷诺氏征患者星状神经节附近的偏振光照射]
Masui. 1992 Nov;41(11):1814-7.
5
[Raynaud's phenomena: diagnostic and treatment study].[雷诺现象:诊断与治疗研究]
Rev Prat. 1998 Oct 1;48(15):1659-64.
6
Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis.用于系统性硬化症中雷诺现象的钙通道阻滞剂。
Arthritis Rheum. 2001 Aug;44(8):1841-7. doi: 10.1002/1529-0131(200108)44:8<1841::AID-ART322>3.0.CO;2-8.
7
[Therapeutic management of acral manifestations of systemic sclerosis].[系统性硬化症肢端表现的治疗管理]
Med Klin (Munich). 2007 Mar 15;102(3):209-18. doi: 10.1007/s00063-007-1025-4.
8
Laser Doppler skin perfusion pressure in the assessment of Raynaud's phenomenon.激光多普勒皮肤灌注压在雷诺现象评估中的应用
Eur J Vasc Endovasc Surg. 2004 Apr;27(4):414-6. doi: 10.1016/j.ejvs.2003.12.017.
9
A case of spinal cord stimulation in Raynaud's Phenomenon: can subthreshold sensory stimulation have an effect?雷诺现象中脊髓刺激的一例病例:阈下感觉刺激会有效果吗?
Pain Physician. 2007 May;10(3):473-8.
10
[Medical and surgical treatment of Raynaud's phenomenon].雷诺现象的医学与外科治疗
Phlebologie. 1987 Jan-Mar;40(1):51-4.

引用本文的文献

1
Chemogenetics: Beyond Lesions and Electrodes.化学生物学:超越损伤和电极。
Neurosurgery. 2021 Jul 15;89(2):185-195. doi: 10.1093/neuros/nyab147.
2
[Therapeutic management in early disease stages of systemic sclerosis : early diagnosis - early symptoms - early problems].系统性硬化症疾病早期阶段的治疗管理:早期诊断 - 早期症状 - 早期问题
Z Rheumatol. 2013 Dec;72(10):960-9. doi: 10.1007/s00393-013-1270-2.
3
Sonographically guided hydrodissection and corticosteroid injection for scleroderma hand.超声引导下硬化性掌挛缩的水分离及皮质类固醇注射治疗
Clin Rheumatol. 2011 Jun;30(6):805-13. doi: 10.1007/s10067-010-1653-6. Epub 2011 Jan 15.
4
Raynaud's phenomenon.
Curr Treat Options Cardiovasc Med. 2008 Apr;10(2):146-55. doi: 10.1007/s11936-008-0016-y.
5
Treatment of Raynaud's phenomenon: new insights and developments.雷诺现象的治疗:新见解与进展
Curr Rheumatol Rep. 2003 Apr;5(2):168-74. doi: 10.1007/s11926-003-0046-0.